Form SCHEDULE 13D/A Silence Therapeutics Filed by: Griffiths Richard Ian
Tweet
Share
E-mail|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 11)*
|
Silence Therapeutics Plc (Name of Issuer) |
Ordinary Shares, nominal value of PS0.05 per share (Title of Class of Securities) |
(CUSIP Number) |
Richard Griffiths 19-21, Broad Street St Helier, Y9, JE2 3RR 44 1534 517500 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
08/12/2026 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
Richard Griffiths | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
PF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
JERSEY
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
14,391,498.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
7.97 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person:
* Consists of (i) 10,777,044 ordinary shares represented by American Depositary Shares ("ADSs") held by Ora Capital Limited; (ii) 600,000 ordinary shares represented by ADSs held by Cream Capital Limited; and (iii) 3,014,454 ordinary shares represented by ADSs held by Mr. Griffiths. Each ADS represents, and at the holder's option is convertible into, three ordinary shares of the Issuer. Mr. Griffiths is a director and the controlling shareholder of both Ora Capital Limited and Cream Capital Limited and possesses the power to direct the voting and disposition of these shares.
**This percentage is calculated based upon the 180,628,068 outstanding ordinary shares of the Issuer, as disclosed in the Issuer's last SEC filing.
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Ordinary Shares, nominal value of PS0.05 per share | |
| (b) | Name of Issuer:
Silence Therapeutics Plc | |
| (c) | Address of Issuer's Principal Executive Offices:
72 Hammersmith Road, London,
UNITED KINGDOM
, W14 8TH. | |
Item 1 Comment:
This Amendment No. 11 to Schedule 13D (this "Amendment"), which amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on June 15, 2022, as amended on July 20, 2022, October 20, 2022, August 14, 2023, March 27, 2024, December 18, 2024, March 31, 2025, April 24, 2025, May 8, 2025, June 25, 2025 and 6 July 2026 (the "Schedule 13D") on behalf of Richard Ian Griffiths, relates to the ordinary shares, nominal value PS0.05 per share (the "Shares"), of Silence Therapeutics plc (the "Issuer"). This Amendment is being filed to reflect significant dilution as a result of an increase in the share capital of the Issuer together with open market transactions of the Issuer's ADSs by the Reporting Person. Except as amended and supplemented hereby, the Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment but not defined herein shall have the meanings ascribed thereto in the Schedule 13D. | ||
| Item 2. | Identity and Background | |
| (a) | Richard Griffiths | |
| (b) | 19-21 Broad Street, St Helier, Jersey, JE2 3RR | |
| (d) | n/a | |
| (e) | n/a | |
| (f) | Jersey, Channel Islands | |
| Item 3. | Source and Amount of Funds or Other Consideration | |
Mr. Griffiths sold an aggregate of 5,484,320 ADSs in open market transactions between August 10, 2026 and August 12, 2026 for aggregate sales proceeds of $87.7M. | ||
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer | |
n/a | ||
| Item 7. | Material to be Filed as Exhibits. | |
Schedule 1 Transactions in ADSs During the Past Sixty Days | ||
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
ATTACHMENTS / EXHIBITS
Create E-mail Alert Related Categories
SEC FilingsRelated Entities
13DSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
